Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: Data from a Latin American cohort

Lupus

Volumn 22, Issue 9, 2013, Pages 899-907

  Pons Estel, G J ^a,b   Alarcon G S ^b   Burgos, P I ^b,c   Hachuel, L ^d   Boggio, G ^d   Wojdyla, D ^d   Nieto, R ^e   Alvarellos, A ^f   Catoggio, L J ^g   Guibert Toledano, M ^h   Sarano, J ⁱ   Massardo, L ^c   Vasquez G M ^j   Iglesias Gamarra, A ^k   Costallat, Lt Lavras ^l   Da Silva, N A ^m   Alfaro, J L ⁿ   Abadi, I ^o   Segami, M I ^p   Huerta, G ^q   Cardiel, M H ^r   Pons Estel, B A ^s   more..

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^e Hospital Eva Peron   (Argentina)

^f HOSPITAL PRIVADO   (Argentina)

^g HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^h Medical Surgical Research Center   (Cuba)

ⁱ INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^j UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^k UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

ⁿ HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

^o Hospital de Clinicas Caracas   (Venezuela)

^p HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^q Hospital de Especialidades Miguel Hidalgo   (Mexico)

^r SECRETARÍA DE SALUD   (Mexico)

^s Hospital Provincial de Rosario ^*  (Argentina)

more..

Author keywords

antimalarials; ethnicity; nephritis; renal lupus; systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; HYPERTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MESTIZO; ONSET AGE; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEINURIA; RACE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY CAST; ADOLESCENT; COHORT ANALYSIS; ETHNOLOGY; FOLLOW UP; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY DISORDERS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SOUTH AND CENTRAL AMERICA; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIMALARIALS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LATIN AMERICA; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MULTIVARIATE ANALYSIS; PHOTOSENSITIVITY DISORDERS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84880885195     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313496339     Document Type: Article

References (35)

1. Bastian HM, Roseman JM, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002 ; 11: 152-160
2. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med. 1991 ; 91: 345-353
3. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: Ethnic and disease heterogeneity among Hispanics. Medicine (Baltimore). 2004 ; 83: 1-17
4. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the development of lupus nephritis: A retrospective analysis. Am J Med. 2002 ; 112: 726-729
5. Burgos PI, McGwin G, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis. 2011 ; 70: 393-394
6. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: The role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003 ; 18: 2039-2046
7. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum. 1995 ; 38: 274-283
8. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009 ; 48: 542-545
9. Alarcón GS, Bastian HM, Beasley TM, et al. Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] Contributions of admixture and socioeconomic status to renal involvement. Lupus. 2006 ; 15: 26-31
10. Goulet JR, MacKenzie T, Levinton C, Hayslett JP, Ciampi A, Esdaile JM. The longterm prognosis of lupus nephritis: The impact of disease activity. J Rheumatol. 1993 ; 20: 59-65
11. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am. 2000 ; 26: 199-213, v
12. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus. 2008 ; 17: 281-288
13. Pons-Estel GJ, Alarcón GS, McGwin G, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009 ; 61: 830-839
14. Pons-Estel GJ, Alarcón GS, Hachuel L, et al. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: Data from a Latin-American cohort. Rheumatology (Oxford). 2012 ; 51: 1293-1298
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
17. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
18. Bastian HM, Alarcón GS, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: Factors predictive of new or worsening proteinuria. Rheumatology (Oxford). 2007 ; 46: 683-689
19. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006 ; 45: 1144-1147
20. Alarcón GS, McGwin G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002 ; 11: 95-101
21. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ. Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis. 2000 ; 59: 116-119
22. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol. 2007 ; 18: 244-254
23. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006 ; 69: 1846-1851
24. Peschken CA, Katz SJ, Silverman E, et al. The 1000 Canadian faces of lupus: Determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009 ; 36: 1200-1208
25. Sanchez E, Rasmussen A, Riba L, et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 2012 ; 64: 3687-3694
26. Richman IB, Taylor KE, Chung SA, et al. European genetic ancestry is associated with a decreased risk of lupus nephritis. Arthritis Rheum. 2012 ; 64: 3374-3382
27. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 ; 59: 437-447
28. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006 ; 15: 366-370
29. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus. 2006 ; 15: 94-101
30. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol. 1998 ; 274: R1058 - R1064
31. Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA - evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006 ; 2: 458-459
32. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012 ; 8: 522-533
33. Anaya JM, Uribe M, Pérez A, et al. Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia. Biomedica. 2003 ; 23: 293-300
34. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005 ; 14: 890-895
35. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton). 2010 ; 15: 482-490 Skin Diseases